Amy Summy, Chief Marketing Officer of Labcorp, Named to Forbes’ CMO Next
February 16 2021 - 12:59PM
Business Wire
Labcorp (NYSE: LH), a leading global life sciences company,
today announced that Amy Summy, executive vice president and chief
marketing officer, was recognized on the 2021 Forbes CMO Next list
for her leadership during the COVID-19 crisis, while also
spearheading the rebranding strategy that highlighted the power of
Labcorp’s combined diagnostic and drug development businesses.
Forbes also recognized Amy’s work in launching several products,
including the company’s Pixel by Labcorp™ at-home testing kits.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210216006013/en/
Amy Summy, CMO, Labcorp (Photo: Business
Wire)
CMO Next features 50 chief marketing officers who are redefining
the role that marketing plays in their industries. Selected by
editors and outside experts, Forbes CMO Next highlights leaders
that serve as role models in the areas of innovation, technology,
creativity, and culture.
“Making an impact on healthcare and people’s lives is why I
joined Labcorp,” said Summy. “Over 75,000 Labcorp employees have
served on the frontlines fighting COVID-19, and our leadership in
testing and clinical trial capabilities has played a central role
during this unprecedented time. I am honored to be recognized by
Forbes and share this accomplishment with our team for focusing on
bringing the innovation and scientific expertise of Labcorp to
market quickly so we can improve health and improve lives. I look
forward to building on our foundation and working with our teams to
improve patient outcomes in cancer, Alzheimer’s and other
diseases.”
Summy joined Labcorp after serving in marketing, digital and
leadership roles at Ernst & Young, TE Connectivity and Sapient.
She is the co-founder and board member of No More Kids with Cancer
and is a member of the Corporate Council for the Children’s
Hospital of Philadelphia. Her teams have played an important role
in Labcorp’s worldwide response to COVID-19 and recently launched
Labcorp’s new brand, which exemplifies the role Labcorp plays in
guiding health, and its commitment to improving health and
improving lives.
The complete list and profiles of the honorees are available at
https://www.forbes.com/sites/martyswant/2021/02/11/cmo-next-2021-50-innovative-marketers-transforming-business-in-a-changed-world/?sh=445ab84a571e.
About Labcorp Labcorp is a leading global life sciences
company that provides vital information to help doctors, hospitals,
pharmaceutical companies, researchers, and patients make clear and
confident decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and improve lives. With more than
75,000 employees, we serve clients in more than 100 countries.
Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn
more about us at www.Labcorp.com or follow us on LinkedIn and
Twitter @Labcorp.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including
but not limited to statements with respect to recognition and
reputation of the Company. Each of the forward-looking statements
is subject to change based on various important factors, many of
which are beyond the Company’s control, including without
limitation, the COVID-19 pandemic and its impact on our business
and financial condition as well as general economic, business, and
market conditions, competitive actions and other unforeseen changes
and general uncertainties in the marketplace, changes in government
regulations, including healthcare reform, customer purchasing
decisions, including changes in payer regulations or policies,
other adverse actions of governmental and third-party payers,
changes in testing guidelines or recommendations, federal, state,
and local governmental responses to the COVID-19 pandemic, the
effect of public opinion on the Company’s reputation, adverse
results in material litigation matters, failure to maintain or
develop customer relationships, our ability to develop or acquire
new products and adapt to technological changes, failure in
information technology, systems or data security, the number of
revenue days in a financial period, personnel costs, and the effect
of exchange rate fluctuations, and employee relations. These
factors, in some cases, have affected and in the future (together
with other factors) could affect the Company’s ability to implement
the Company’s business strategy and actual results could differ
materially from those suggested by these forward-looking
statements. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements. The Company has
no obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. Further information on potential factors,
risks and uncertainties that could affect operating and financial
results is included in the Company’s most recent Annual Report on
Form 10-K and subsequent Forms 10-Q, including in each case under
the heading RISK FACTORS, and in the Company’s other filings with
the SEC.
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210216006013/en/
Media: Christopher
Allman-Bradshaw — 336-436-8263 Media@Labcorp.com
Investors: Chas Cook —
336-436-5076 Investor@Labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024